Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$127.96 -0.2%	$100.02	$73.04 ▼ $128.34	$8.26B	0.84	1.20 million shs	4.73 million shs
CORT Corcept Therapeutics	$70.06 -1.6%	$71.48	$28.04 ▼ $117.33	$7.43B	0.19	1.14 million shs	1.01 million shs
PRVB Provention Bio	$24.98	$24.58	$3.18 ▼ $25.00	$2.37B	2.47	2.28 million shs	218,200 shs
ROIV Roivant Sciences	$11.32 -1.3%	$10.81	$8.73 ▼ $13.06	$7.70B	1.16	5.60 million shs	5.97 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	-0.19%	+0.09%	+31.23%	+42.84%	+20.56%
CORT Corcept Therapeutics	-1.57%	+0.66%	-1.10%	+25.08%	+114.64%
PRVB Provention Bio	0.00%	0.00%	0.00%	0.00%	0.00%
ROIV Roivant Sciences	-1.31%	+0.80%	+6.09%	+6.19%	+4.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	1.0505 of 5 stars	2.2	2.0	0.0	0.0	2.2	0.8	0.6
CORT Corcept Therapeutics	4.5886 of 5 stars	3.5	1.0	0.0	4.2	2.7	4.2	1.9
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	2.2343 of 5 stars	3.5	3.0	0.0	0.0	1.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.32	Hold	$129.35	1.09% Upside
CORT Corcept Therapeutics	3.00	Buy	$138.25	97.33% Upside
PRVB Provention Bio	0.00	N/A	N/A	N/A
ROIV Roivant Sciences	3.00	Buy	$17.50	54.59% Upside

Current Analyst Ratings Breakdown

Latest PRVB, BPMC, CORT, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
6/3/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$150.00 ➝ $135.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$562.12M	14.70	N/A	N/A	$4.67 per share	27.40
CORT Corcept Therapeutics	$685.45M	10.84	$1.03 per share	67.96	$4.92 per share	14.24
PRVB Provention Bio	$12.90M	183.54	N/A	N/A	$1.40 per share	17.84
ROIV Roivant Sciences	$29.05M	264.87	N/A	N/A	$7.76 per share	1.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	196.86	N/A	-13.19%	-77.49%	-20.84%	7/30/2025 (Estimated)
CORT Corcept Therapeutics	$106.14M	$1.16	55.60	37.87	N/A	22.35%	24.54%	20.24%	8/4/2025 (Estimated)
PRVB Provention Bio	-$113.57M	-$1.53	N/A	N/A	N/A	-880.69%	-103.36%	-69.08%	N/A
ROIV Roivant Sciences	$4.35B	-$0.25	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	8/6/2025 (Estimated)

Latest PRVB, BPMC, CORT, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.15	2.85	2.80
CORT Corcept Therapeutics	0.01	3.70	3.64
PRVB Provention Bio	0.19	1.93	1.92
ROIV Roivant Sciences	N/A	37.91	37.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
CORT Corcept Therapeutics	93.61%
PRVB Provention Bio	37.39%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
CORT Corcept Therapeutics	20.80%
PRVB Provention Bio	13.10%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
CORT Corcept Therapeutics	300	106.05 million	83.30 million	Optionable
PRVB Provention Bio	82	94.78 million	82.37 million	Not Optionable
ROIV Roivant Sciences	860	679.81 million	657.18 million	Optionable

PRVB, BPMC, CORT, and ROIV Headlines

Recent News About These Companies

Roivant Sciences à la conférence Goldman Sachs : focus sur l’exécution stratégique

June 10, 2025 | fr.investing.com

Roivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PM

June 10, 2025 | zonebourse.com

GAMMA Investing LLC Has $6.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 10, 2025 | marketbeat.com

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 9, 2025 | globenewswire.com

Vivek Ramaswamy Sells 547,430 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

June 8, 2025 | americanbankingnews.com

Selon un récent dépôt auprès de la SEC, un initié de Roivant Sciences a vendu des actions pour une valeur de 8 454 808 dollars.

June 7, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 200,800 Shares

June 7, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $2,246,952.00 in Stock

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 547,430 Shares

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 04:20 PM

June 6, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 566,278 Shares of Stock

June 5, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | insidertrades.com

California State Teachers Retirement System Acquires 37,982 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

June 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Trading 5.5% Higher - Here's Why

May 30, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS

May 30, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript

May 30, 2025 | insidermonkey.com

What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings

May 30, 2025 | finance.yahoo.com

Why Roivant Sciences Ltd. (ROIV) Surged On Thursday

May 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRVB, BPMC, CORT, and ROIV Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$127.96 -0.25 (-0.19%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$128.38 +0.42 (+0.32%)

As of 06/13/2025 05:27 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Corcept Therapeutics NASDAQ:CORT

$70.06 -1.12 (-1.57%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$70.12 +0.06 (+0.09%)

As of 06/13/2025 07:53 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Provention Bio NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Roivant Sciences NASDAQ:ROIV

$11.32 -0.15 (-1.31%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$11.30 -0.02 (-0.18%)

As of 06/13/2025 04:44 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time